Literature DB >> 19795923

C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes.

Y-Y Zhang1, Y Liu, J-W Zhang, G-B Ge, H-X Liu, L-M Wang, J Sun, L Yang.   

Abstract

Taxanes exhibit a high tendency to epimerize at C-7 under physiological conditions. This study aimed to investigate the composite effect of C-7 configuration and other substructural elements on the metabolic properties of taxanes. Cephalomannine, 7-epi-cephalomannine, 10-deacetyl-paclitaxel, and 7-epi-10-deacetyl-paclitaxel were chosen as model compounds. In human liver microsomes, 7-epi-cephalomannine was subject to C-13 lateral chain (M-1) and diterpenoid core monohydroxylation (M-2), mediated by cytochrome P450 (CYP) 3A4 and CYP2C8, respectively. However, only one 7-epi-10-deacetyl-paclitaxel metabolite (M), monohydroxylated at taxane ring by CYP2C8, was detected. In comparison with cephalomannine, the catalytic efficiency of CYP2C8 for 7-epi-cephalomannine was about five-fold higher due to the decreased K(m). Although CYP2C8 showed a high capacity for metabolizing 7-epi-10-deacetyl-paclitaxel, 10-deacetyl-paclitaxel was hardly metabolized under the identical incubation conditions. In conclusion, C-7 configuration represents one of the most important structural determinants in taxanes metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19795923     DOI: 10.3109/00498250903271989

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.

Authors:  Pei-pei Dong; Zhong-ze Fang; Yan-yan Zhang; Guang-bo Ge; Yu-xi Mao; Liang-liang Zhu; Yan-qing Qu; Wei Li; Li-ming Wang; Chang-xiao Liu; Ling Yang
Journal:  Acta Pharmacol Sin       Date:  2011-03       Impact factor: 6.150

2.  Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes.

Authors:  Zhongnv Ma; Xianbao Shi; Gang Zhang; Feng Guo; Lina Shan; Jiqun Cai
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-10       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.